Institutional members access full text with Ovid®

Share this article on:

Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis

Chu, Yanxiaa; Zheng, Aia; Wang, Feib; Lin, Weia; Yang, Xiaoyuna; Han, Linga; Chen, Yalia; Bai, Lipinga

Nuclear Medicine Communications: February 2014 - Volume 35 - Issue 2 - p 144–150
doi: 10.1097/MNM.0000000000000026
Original Articles

Objectives Accurate detection of recurrent cervical cancer remains a clinical difficulty. This study aims to assess the diagnostic value of PET or PET-computed tomography (PET-CT) using 18F-fluorodeoxyglucose (18F-FDG) in recurrent cervical cancer using a meta-analysis.

Study design All published studies in English evaluating the diagnostic value of PET or PET-CT in detecting recurrent cervical cancer were collected. The methodological quality of the included studies was evaluated. Pooled sensitivity, specificity, diagnostic odds ratio, and summary receiver-operating characteristic curves were obtained using statistical software. Twenty studies were included in the meta-analysis.

Results The meta-analysis showed that the pooled sensitivity and specificity of PET and PET-CT to detect distant metastasis in recurrent cervical cancer were 0.87 [95% confidence interval (CI): 0.80–0.92] and 0.97 (95% CI: 0.96–0.98), respectively. The pooled sensitivity and specificity for local regional recurrence were 0.82 (95% CI: 0.72–0.90) and 0.98 (95% CI: 0.96–0.99), respectively.

Conclusion 18F-FDG-PET and PET-CT are valuable methods for the assessment of recurrent cervical cancer.

aDepartment of Obstetric and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China

bDepartment of Obstetric and Gynecology, People's Hospital of Shanxi Province, 256 Xi'an Friendship West Road, Shanxi 710068, China

Correspondence to Ai Zheng, MD, Department of Obstetric and Gynecology, West China Second University Hospital, Sichuan University, Section 3, 20S. Renmin Road, Chengdu, Sichuan 610041, China Tel: +86 28 85503960; fax: +86 28 85559065; e-mail:

Received September 10, 2013

Accepted October 1, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins